HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy

乙型肝炎表面抗原 医学 内科学 HBeAg 抗病毒治疗 抗病毒治疗 病毒学 乙型肝炎病毒 免疫学 慢性肝炎 病毒
作者
Milan J. Sonneveld,Shao‐Ming Chiu,Jun Yong Park,Sylvia M. Brakenhoff,Apichat Kaewdech,Wai‐Kay Seto,Yasuhito Tanaka,Ivana Carey,Μargarita Papatheodoridi,Piero Colombatto,Florian van Bömmel,Harry L.A. Janssen,Thomas Berg,Fabien Zoulim,Sang Hoon Ahn,George Ν. Dalekos,Nicole Stephanie Erler,Maurizia Rossana Brunetto,Heiner H. Wedemeyer,Markus Cornberg
出处
期刊:Gastroenterology [Elsevier BV]
卷期号:166 (1): 168-177.e8 被引量:29
标识
DOI:10.1053/j.gastro.2023.09.033
摘要

BACKGROUND & AIMS: Patients who discontinue nucleo(s)tide analogue therapy are at risk of viral rebound and severe hepatitis flares, necessitating intensive off-treatment follow-up. METHODS: We studied the association between hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA levels at off-treatment follow-up week 24 (FU W24), with subsequent clinical relapse, and HBsAg loss in a multicenter cohort of hepatitis B e antigen (HBeAg)-negative patients with chronic hepatitis B who discontinued nucleo(s)tide analogue therapy. RESULTS: We studied 475 patients, 82% Asian, and 55% treated with entecavir. Patients with higher HBV DNA levels at FU W24 had a higher risk of clinical relapse (hazard ratio [HR], 1.576; P < .001) and a lower chance of HBsAg loss (HR, 0.454; P < .001). Similarly, patients with higher HBsAg levels at FU W24 had a higher risk of clinical relapse (HR, 1.579; P < .001) and a lower chance of HBsAg loss (HR, 0.263; P < .001). A combination of both HBsAg <100 IU/mL and HBV DNA <100 IU/mL at FU W24 identified patients with excellent outcomes (9.9% clinical relapse and 58% HBsAg loss at 216 weeks of follow-up). Conversely, relapse rates were high and HBsAg loss rates negligible among patients with both HBsAg >100 IU/mL and HBV DNA >100 IU/mL (P < .001). CONCLUSIONS: Among HBeAg-negative patients with chronic hepatitis B who discontinued antiviral therapy and who did not experience clinical relapse before FU W24, serum levels of HBV DNA and HBsAg at FU W24 can be used to predict subsequent clinical relapse and HBsAg clearance. A combination of HBsAg <100 IU/mL with HBV DNA <100 IU/mL identifies patients with a low risk of relapse and excellent chances of HBsAg loss and could potentially be used as an early surrogate end point for studies aiming at finite therapy in HBV.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ava的应助被于子超采纳,获得10
1秒前
1秒前
LuXiaoyu的应助被LJH采纳,获得10
1秒前
LuXiaoyu的应助被LJH采纳,获得10
2秒前
mechefy完成签到 ,获得积分10
2秒前
LuXiaoyu的应助被LJH采纳,获得10
2秒前
隐形曼青的应助被777采纳,获得10
4秒前
感动沛容完成签到,获得积分10
4秒前
李健的应助被hyphen采纳,获得10
4秒前
科目三的应助被hyphen采纳,获得10
5秒前
科目三的应助被Jcxx采纳,获得10
5秒前
小鱼完成签到 ,获得积分10
5秒前
拉普拉斯开始变换完成签到,获得积分10
5秒前
6秒前
7秒前
丘比特的应助被研通采纳,获得10
7秒前
于子超完成签到,获得积分20
7秒前
7秒前
8秒前
9秒前
10秒前
Lomungii发布了新的文献求助30
13秒前
13秒前
章鱼小丸子完成签到,获得积分10
14秒前
今后的应助被简单酒窝采纳,获得10
14秒前
852的应助被火星上梦安采纳,获得10
14秒前
Prospect发布了新的文献求助10
14秒前
14秒前
研友_VZG7GZ的应助被王兵采纳,获得10
15秒前
16秒前
dkk发布了新的文献求助10
17秒前
开心德地发布了新的文献求助10
17秒前
bowen完成签到,获得积分10
17秒前
18秒前
19秒前
19秒前
19秒前
19秒前
19秒前
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189137
求助须知:如何正确求助?哪些是违规求助? 9576601
关于积分的说明 21848766
捐赠科研通 7787145
什么是DOI,文献DOI怎么找? 3435490
关于科研通互助平台的介绍 2559732
邀请新用户注册赠送积分活动 2482462